Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 17Leukemia 12Breast Neoplasms 12Prostatic Neoplasms 10Neoplasm Metastasis 8Recurrence 6Pancreatic Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Philadelphia Chromosome 4Multiple Myeloma 4Lymphoma 4Burkitt Lymphoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Ovarian Neoplasms 3Glioma 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neuroblastoma 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Cyclophosphamide 30fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Tacrolimus 17Mycophenolic Acid 16Methotrexate 16Whole-Body Irradiation 14Etoposide 13Vincristine 12Doxorubicin 12Dexamethasone 11Busulfan 11Cytarabine 10Antilymphocyte Serum 10venetoclax 9Prednisone 9nelarabine 8Rituximab 8Filgrastim 8Cyclosporine 8Calcium Dobesilate 8merphos 7Melphalan 7Radiotherapy 6prednylidene 5deltacortene 5Methylprednisolone 5Azacitidine 5Sirolimus 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Dasatinib × Clear all
NCT00792948 2026-05-29

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
97 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06390319 2026-05-01

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

St. Jude Children's Research Hospital

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡